NCT01194167

Study of Eltrombopag in Platelet Refractory Thrombocytopenia

A Phase II Study of Eltrombopag in Platelet Refractory Thrombocytopenia

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia (low platelet count). Eltrombopag is approved by the FDA for the treatment of thrombocytopenia (low platelet count) in adults who have had an insufficient response to medications such as corticosteroids and immunoglobulins. Eltrombopag is not approved by the FDA (Food and Drug Administration) for the treatment of thrombocytopenia refractory to platelet transfusion and so for this study is considered investigational.

Conditions

• Thrombocytopenia

Interventions

Type	Name	Description
DRUG	Eltrombopag	75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day

Timeline

• Start date: 2010-08-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2010-09-02
• Last updated: 2019-11-25

Locations

1 site across 1 country: United States